FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W56378889> ?p ?o ?g. }

• W56378889 endingPage "10" @default.
• W56378889 startingPage "905" @default.
• W56378889 abstract "Lowering intraocular pressure (IOP) is currently the only therapeutic approach in primary open-angle glaucoma. and the fixed-combination medications are needed to achieve sufficiently low target IOP. A multicenter prospective study in the Chinese population was needed to confirm the safety and efficacy of Bimatoprost/Timolol Fixed Combination Eye Drop in China. In this study, we evaluated the safety and efficacy of Bimatoprost/Timolol Fixed Combination with concurrent administration of its components in Chinese patients with open-angle glaucoma or ocular hypertension.In this multicenter, randomized, double-masked, parallel controlled study, patients with open-angle glaucoma or ocular hypertension who were insufficiently responsive to monotherapy with either topical β-blockers or prostaglandin analogues were randomized to one of two active treatment groups in a 1:1 ratio at 11 Chinese ophthalmic departments. Bimatoprost/timolol fixed combination treatment was a fixed combination of 0.03% bimatoprost and 0.5% timolol (followed by vehicle for masking) once daily at 19:00 P.M. and concurrent treatment was 0.03% bimatoprost followed by 0.5% timolol once daily at 19:00 P.M. The primary efficacy variable was change from baseline in mean diurnal intraocular pressure (IOP) at week 4 visit in the intent-to-treat (ITT) population. Primary analysis evaluated the non-inferiority of bimatoprost/ timolol fixed combination to concurrent with respect to the primary variable using a confidence interval (CI) approach. Bimatoprost/timolol fixed combination was to be considered non-inferior to concurrent if the upper limit of the 95% CI for the between-treatment (bimatoprost/timolol fixed combination minus concurrent) difference was ≤ 1.5 mmHg. Adverse events were collected and slit-lamp examinations were performed to assess safety. Between-group comparisons of the incidence of adverse events were performed using the Pearson chi-square test or Fisher's exact test.Of the enrolled 235 patients, 121 patients were randomized to receive bimatoprost/timolol fixed combination and, 114 patients were randomized to receive concurrent treatment. At baseline the mean value of mean diurnal IOP was (25.20 ± 3.06) mmHg in the bimatoprost/timolol fixed combination group and (24.87 ± 3.88) mmHg in the concurrent group. The difference between the treatment groups was not statistically significant. The mean change from baseline in mean diurnal IOP (± standard deviation) in the bimatoprost/timolol fixed combination group was (-9.38 ± 4.66) mmHg and it was (-8.93 ± 4.25) mmHg in the concurrent group (P < 0.01). The difference between the two treatment groups (bimatoprost/timolol fixed combination minus concurrent) in the change from baseline of mean diurnal IOP was -0.556 mmHg (95% CI: -1.68, 0.57, P = 0.330). The upper limit of the 95% CI was less than 1.5 mmHg, the predefined margin of non-inferiority. Adverse events occurred in 26.4% (32/121) of the bimatoprost/timolol fixed combination patients and 30.7% (35/114) of the concurrent patients. The most frequent adverse event was conjunctival hyperemia, which was reported as treatment related in 16.5% (20/121) in the bimatoprost/timolol fixed combination group and 18.4% (21/114) in the concurrent group (P > 0.05).Bimatoprost/Timolol Fixed Combination administered in Chinese patients with open-angle glaucoma or ocular hypertension was not inferior to concurrent dosing with the individual components. Safety profiles were similar between the treatment groups." @default.
• W56378889 created "2016-06-24" @default.
• W56378889 creator A5003463555 @default.
• W56378889 creator A5020659279 @default.
• W56378889 creator A5032700450 @default.
• W56378889 creator A5034947642 @default.
• W56378889 creator A5039092963 @default.
• W56378889 creator A5040096906 @default.
• W56378889 creator A5040239180 @default.
• W56378889 creator A5044302709 @default.
• W56378889 creator A5051618213 @default.
• W56378889 creator A5057558848 @default.
• W56378889 creator A5064527448 @default.
• W56378889 creator A5070684523 @default.
• W56378889 creator A5074509527 @default.
• W56378889 date "2014-01-01" @default.
• W56378889 modified "2023-10-18" @default.
• W56378889 title "Safety and efficacy of bimatoprost/timolol fixed combination in Chinese patients with open-angle glaucoma or ocular hypertension." @default.
• W56378889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24571886" @default.
• W56378889 hasPublicationYear "2014" @default.
• W56378889 type Work @default.
• W56378889 sameAs 56378889 @default.
• W56378889 citedByCount "4" @default.
• W56378889 countsByYear W563788892015 @default.
• W56378889 countsByYear W563788892017 @default.
• W56378889 countsByYear W563788892022 @default.
• W56378889 crossrefType "journal-article" @default.
• W56378889 hasAuthorship W56378889A5003463555 @default.
• W56378889 hasAuthorship W56378889A5020659279 @default.
• W56378889 hasAuthorship W56378889A5032700450 @default.
• W56378889 hasAuthorship W56378889A5034947642 @default.
• W56378889 hasAuthorship W56378889A5039092963 @default.
• W56378889 hasAuthorship W56378889A5040096906 @default.
• W56378889 hasAuthorship W56378889A5040239180 @default.
• W56378889 hasAuthorship W56378889A5044302709 @default.
• W56378889 hasAuthorship W56378889A5051618213 @default.
• W56378889 hasAuthorship W56378889A5057558848 @default.
• W56378889 hasAuthorship W56378889A5064527448 @default.
• W56378889 hasAuthorship W56378889A5070684523 @default.
• W56378889 hasAuthorship W56378889A5074509527 @default.
• W56378889 hasConcept C118487528 @default.
• W56378889 hasConcept C2776521421 @default.
• W56378889 hasConcept C2777336333 @default.
• W56378889 hasConcept C2778073030 @default.
• W56378889 hasConcept C2778527774 @default.
• W56378889 hasConcept C2781092963 @default.
• W56378889 hasConcept C2908647359 @default.
• W56378889 hasConcept C2991803831 @default.
• W56378889 hasConcept C42219234 @default.
• W56378889 hasConcept C71924100 @default.
• W56378889 hasConcept C99454951 @default.
• W56378889 hasConceptScore W56378889C118487528 @default.
• W56378889 hasConceptScore W56378889C2776521421 @default.
• W56378889 hasConceptScore W56378889C2777336333 @default.
• W56378889 hasConceptScore W56378889C2778073030 @default.
• W56378889 hasConceptScore W56378889C2778527774 @default.
• W56378889 hasConceptScore W56378889C2781092963 @default.
• W56378889 hasConceptScore W56378889C2908647359 @default.
• W56378889 hasConceptScore W56378889C2991803831 @default.
• W56378889 hasConceptScore W56378889C42219234 @default.
• W56378889 hasConceptScore W56378889C71924100 @default.
• W56378889 hasConceptScore W56378889C99454951 @default.
• W56378889 hasIssue "5" @default.
• W56378889 hasLocation W563788891 @default.
• W56378889 hasOpenAccess W56378889 @default.
• W56378889 hasPrimaryLocation W563788891 @default.
• W56378889 hasRelatedWork W179785385 @default.
• W56378889 hasRelatedWork W1976486265 @default.
• W56378889 hasRelatedWork W2006614849 @default.
• W56378889 hasRelatedWork W2007936429 @default.
• W56378889 hasRelatedWork W2029042302 @default.
• W56378889 hasRelatedWork W2055821100 @default.
• W56378889 hasRelatedWork W2086508188 @default.
• W56378889 hasRelatedWork W2162221629 @default.
• W56378889 hasRelatedWork W2322571957 @default.
• W56378889 hasRelatedWork W2337733503 @default.
• W56378889 hasVolume "127" @default.
• W56378889 isParatext "false" @default.
• W56378889 isRetracted "false" @default.
• W56378889 magId "56378889" @default.
• W56378889 workType "article" @default.